Detournay, Bruno http://orcid.org/0000-0001-7843-4608
Boultif, Zahra
Bahloul, Amar
Jeanbat, Viviane
Robert, Julien
Funding for this research was provided by:
Sanofi france
Article History
Accepted: 21 October 2020
First Online: 20 November 2020
Declarations
:
: This study was funded by Sanofi France, manufacturers of glargine 300 U/ml and branded glargine 100 U/ml.
: VJ, JR and BD are employed by CEMKA, a research and consulting firm providing studies and advisory services for private and public organizations. BD has served as an advisor, consultant or member of a speaker bureau for Merck Sharpe & Dohme Corp., Novo Nordisk, Pfizer Inc. and Sanofi-Aventis. ZB and AB are employees of Sanofi France.
: The study was performed in accordance with relevant international and national legislation for medical research and with good epidemiological practice. The survey protocol was submitted for evaluation to the Comité de Protection des Personnes Nord-Ouest (Ethics Advisory Board) and have respected the obligations defined by the French Law ‘Informatique et Liberté’, which ensures that all medical information is kept confidential and anonymous. All patient data were anonymised before transmission by the pharmacist to the operational centre for entry into the study database, in which each patient was identified by a number.
: European regulations mean that the original database is no longer available. However, full calculations are available from the authors upon request.
: Informed consent was obtained from all individual participants.
: Patients’ consent to participate was obtain by the participating pharmacist (investigators). Data were collected and analyzed on a on a strictly anonymous basis.
: Not applicable.
: Not applicable.
: BD conceived and designed the analysis, interpreted the results and wrote the paper. ZB and AB revised the study protocol and contributed to the paper. VJ collected the data and conducted the data management. JR performed all statistical and economic analyses.